Oxford Biomedica (LON:OXB) Stock Price Passes Below 200 Day Moving Average – Time to Sell?

Oxford Biomedica plc (LON:OXB)’s share price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 663.28 and traded as low as GBX 586. Oxford Biomedica shares last traded at GBX 606.25, with a volume of 425,721 shares changing hands.

Analysts Set New Price Targets

A number of research firms recently commented on OXB. Royal Bank Of Canada decreased their target price on Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating on the stock in a research report on Wednesday, June 24th. Jefferies Financial Group restated a “buy” rating and set a GBX 8.27 price target on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of GBX 600.04.

Oxford Biomedica Trading Up 2.2%

The company has a market cap of £754.33 million, a PE ratio of -23.15 and a beta of 1.12. The stock’s 50 day moving average is GBX 614.11 and its 200-day moving average is GBX 663.28. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 162.16.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.